Zymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio of licensed healthcare assets and pipeline of novel biotherapeutics.

Zymeworks announced six poster presentations at AACR 2026 showcasing preclinical data from its antibody-drug conjugate (ADC) pipeline, including novel RAS-targeting platforms and multiple first-in-class programs. The company highlighted efficacy and favorable tolerability across solid tumor models, with clinical data from the Phase 1 ZW191 trial to be presented in an oral presentation on April 21.

Zymeworks Inc. announced the full-time appointments of Dr. Adam Schayowitz as Executive Vice President and Head of R&D, and Scott Platshon as Executive Vice President and Chief Business Officer, effective April 9, 2026. Both executives, previously in interim roles, will report to CEO Kenneth Galbraith. The appointments come as Zymeworks focuses on executing its pipeline strategy, managing licensed assets including Ziihera® (zanidatamab-hrii) and pasritamig, and advancing its asset aggregation strategy to drive long-term shareholder value.

Zymeworks Inc. announced the appointment of Kristin Stafford as Chief Financial Officer effective April 1, 2026. Stafford brings extensive experience from Royalty Pharma in strategic planning, capital allocation, and executing complex transactions. The appointment comes as Zymeworks continues advancing its pipeline of biotherapeutics and executing strategic priorities.

Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα) for treating advanced or metastatic platinum-resistant ovarian cancer. The designation expedites development and review timelines for drugs addressing serious conditions with unmet medical needs. ZW191 is currently in Phase 1 clinical trials evaluating safety, tolerability, and anti-tumor activity in patients with advanced solid tumors.

Zymeworks Inc. announced that management will participate in upcoming investor conferences including the Needham 25th Annual Virtual Healthcare Conference on April 15 and the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21 in Toronto. The company will present clinical and preclinical data on its pipeline programs.

Zymeworks Inc. announced it will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call at 8:30 am ET. The biotechnology company is managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics, with key products including Ziihera and partnerships with BeOne Medicines and Jazz Pharmaceuticals for commercialization rights.

Zymeworks Inc. announced that its management will participate in multiple investor conferences in February and March 2026, including Citi's Virtual Oncology Leadership Summit, TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Citizens Life Science Conference. The company continues to advance its portfolio of licensed healthcare assets and biotherapeutics pipeline.

Jazz Pharmaceuticals announced positive Phase 3 trial results for Ziihera (zanidatamab-hrii) in treating HER2-positive gastroesophageal adenocarcinoma. The triplet therapy combining Ziihera with tislelizumab and chemotherapy achieved a median overall survival of 26.4 months, the longest reported in a Phase 3 GEA trial, representing a 28% reduction in death risk. The doublet therapy also showed strong results with median OS of 24.4 months. Jazz shares rose 2.07% following the announcement.

Zymeworks announced positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival (approximately 35% risk reduction) and overall survival (26.4 months median, representing a 7+ month improvement over trastuzumab). Zymeworks is eligible to receive up to $440 million in milestone payments from regulatory approvals across major markets.

Zymeworks Inc. will participate in two upcoming healthcare investor conferences in Miami, including one-on-one meetings and fireside chats, highlighting their biotechnology portfolio and licensed healthcare assets.

Zymeworks, Jazz Pharmaceuticals, and BeOne Medicines reported positive Phase 3 trial results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, demonstrating significant improvements in progression-free and overall survival.